Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.

Five-year-olds can be goofy. That was my first thought several years ago when my son stumbled and fell to the ground.

Five-year-olds can be goofy. That was my first thought several years ago when my son stumbled and fell to the ground. But when he failed to get up and told ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

Now since those early days I have learnt that no one is owed my medical information, but I continue to share what I am comfortable with as I think rare disease awareness is crucial. The world of rare ...

The phase IIb study is evaluating batoclimab in CIDP patients whose disease had worsened during standard-of-care treatment. CIDP is a rare autoimmune neurological disorder that causes progressive ...

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

‘It feels like my body has fallen off a cliff’: The patients still living with long Covid While much of the world has moved on from the pandemic, many continue to battle health problems Save ...